Brief Analysis of Xinlitai’s 2022 First Quarterly Report
This quarterly report is very simple. The company has begun to enter the rising cycle that a normal innovative pharmaceutical company should enter. In the first quarter of 2022, the revenue will be about 935 million, a year-on-year increase of 22%, and the net profit will be about 237 million, a year-on-year increase of 53%; […]
Brief Analysis of Xinlitai’s 2022 First Quarterly Report Read More »